ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Plasma Deal To Join Grifols And Talecris

by Michael McCoy
June 14, 2010 | APPEARED IN VOLUME 88, ISSUE 24

Grifols, a Spanish producer of plasma protein therapies, has agreed to acquire U.S.-based Talecris for about $3.4 billion. Talecris, a former Bayer business that also develops therapies from blood plasma, has been an acquisition candidate since June 2009, when the Federal Trade Commission blocked Australian plasma protein firm CSL from buying it for $3.1 billion. If this deal is approved, it will result in a company with about $2.8 billion in annual sales.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment